Overview

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

Status:
COMPLETED
Trial end date:
2024-05-20
Target enrollment:
Participant gender:
Summary
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk
Phase:
PHASE3
Details
Lead Sponsor:
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Treatments:
Alendronate
Injections
Teriparatide